CHOLESTECH CORPORATION – Trademark Portfolio
Entity Type: 03
CHOLESTECH CORPORATION holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 12 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CHOLESTECH L D X. The owner is based in HAYWARD, CA.
3347 INVESTMENT BOULEVARD
HAYWARD, CA 94545
Showing of trademarks Trademarks
Trademark Classifications
CHOLESTECH CORPORATION's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Education; providing of training; entertainment; sporting and cultural activities
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does CHOLESTECH CORPORATION have?
CHOLESTECH CORPORATION has 16 U.S. trademarks filed with the USPTO. Of these, 1 registered, 11 abandoned, 4 cancelled.
What trademark classes does CHOLESTECH CORPORATION file in?
CHOLESTECH CORPORATION files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 41 (Education & Entertainment), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are CHOLESTECH CORPORATION's most well-known trademarks?
CHOLESTECH CORPORATION's registered trademark portfolio includes well-known marks such as CHOLESTECH L D X. These are among 1 currently registered trademark in the portfolio.
What is CHOLESTECH CORPORATION's trademark registration success rate?
CHOLESTECH CORPORATION has a 6% trademark registration rate, with 1 out of 16 resolved applications resulting in successful registration. Currently, 0 applications are pending review.